Protocol Ledger

NCT07745361 · Phase II · RECRUITING

Study of Oral MRT-2359 With Apalutamide in Prostate Cancer

Interventional Phase II clinical trial protocol NCT07745361 sponsored by Monte Rosa Therapeutics in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-08-18 Enrollment: 25 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07745361
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)25 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07745361
Protocol FieldVerified Registry Value
NCT IdentifierNCT07745361
Consolidated Lead SponsorMonte Rosa Therapeutics
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment25 participants (ESTIMATED)
Registered Start Date2026-08-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07745361
Hospital Research SiteLocationSite Profile
Hoag Memorial Hospital PresbyterianNewport Beach, CAOpen Hospital Dossier ->
University of Maryland/Greenebaum Cancer CenterBaltimore, MDOpen Hospital Dossier ->
Levine Cancer InstituteCharlotte, NCOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI